Precision Biosciences (DTIL) Cash & Equivalents (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Cash & Equivalents data on file, last reported at $99.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 28.68% year-over-year to $99.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.4 million (up 28.68% YoY) and the FY2025 annual result came in at $110.8 million, up 29.02% from the prior year.
• Cash & Equivalents retreated to $99.4 million in Q1 2026 per DTIL's latest filing, from $110.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $212.1 million in Q3 2022 and bottomed at $44.9 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $116.7 million (2023), against an average of $122.2 million.
• The widest annual swing landed in 2023, when Cash & Equivalents surged 36.06%; it then slumped 54.56% in 2025.
• Tracing DTIL's Cash & Equivalents over 5 years: stood at $189.6 million in 2022, then sank by 38.45% to $116.7 million in 2023, then fell by 26.38% to $85.9 million in 2024, then increased by 29.02% to $110.8 million in 2025, then dropped by 10.33% to $99.4 million in 2026.
• Per Business Quant, the three latest DTIL Cash & Equivalents figures stand at $99.4 million (Q1 2026), $110.8 million (Q4 2025), and $44.9 million (Q3 2025).

Peer Comparison